Skip to main content

Pulse check: The tenuous state of global pharma

DSC08185
Pulse

If you’ve been following our commentary over the last year, you’ll know that our holdings in the healthcare sector – in particular, pharma companies and their suppliers – have experienced challenging performance.

In 2021, these companies were heroes. Thermo Fisher produced more Covid tests than any other company in the world. AstraZeneca manufactured a Covid vaccine that helped get us out of the pandemic’s grip.  ICON, a clinical research organisation, partnered with Pfizer to progress their vaccine’s clinical trials at unprecedented speed.

But much like any machine that is driven full throttle for too long, the pharma industry burnt out in 2022 following the enormous disruption from the pandemic.

Five years after our first lockdown, when will this industry find its ‘new normal’?

Health is wealth – or is it the other way around?

The average cost to develop a new drug is over $2billion1. For this reason, funding for biopharma research is the lifeforce of the industry. The more funding there is, the more work there is for companies like ICON and Thermo Fisher, and the greater the likelihood of a new drug making it to commercialisation.

We saw a massive influx of biopharma funding during the peak of the pandemic. This sharply tapered in 2022 as the world contended with higher interest rates and economic uncertainty, and as large amounts of funding had been expended to fight Covid.

In March, clinical research company IQVIA published their annual update on pharma R&D2. We were strongly encouraged by the return to funding growth shown in their data, implying the industry’s possible return to health.

Biopharma funding levels US$Bn, 2015-2024

Biopharma funding level chart   cropped

Source: BioWorld, Janaury 2025.

Trump’s policies may be a bitter pill to swallow

While this data is encouraging, we cannot yet give the pharma industry a clean bill of health.

Almost every industry in our portfolio has suffered to some degree from Trump’s obstinate approach to trade negotiations. Given the often life-saving impact of many pharmaceutical therapies, one might have thought that these products might have been exempted from horse-trading over tariffs, but sadly not.

The sector’s share prices have whipsawed this month as we await a likely implementation of US import taxes on pharmaceuticals.

Tariffs are not the only means by which Trump has targeted pharmaceutical companies. His administration directly cut funding to the National Institute of Health (NIH)– cutting nearly 700 grants, worth around $2billion, in just 40 days3. A ‘Most Favored Nations’ policy, which aims to cut drug prices for Medicare patients, similarly seeks to cut American spending on healthcare.

The NIH is overseen by the US Health Secretary, in this case Robert F Kennedy, who has been known to share spurious and poorly evidenced views on healthcare issues.

However, the bigger force at play here is President Trump’s trade negotiations – his aim is to force Europe to carry a greater share of global R&D investment, and he hopes to achieve this by cutting US spending.

This has spooked the sector. What had looked like a healthy recovery in 2024 is now looking less certain.

Portfolio thoughts

Around 20% of our portfolio is in companies that create pharmaceutical therapies, or provide services and support to healthcare R&D.

We do not invest directly in small cap biopharma companies, which are most vulnerable to funding cuts. Our larger pharmaceutical companies, such as AstraZeneca, are much better placed to navigate this difficult geopolitical environment and to fund their own R&D from their profits.

AstraZeneca will be able to manufacture most of what they need on US soil, and the company continues on its mission to launch 20 new medicines by the end of the decade. They believe this will help them reach $80billion in revenue by 2030.

However, our R&D service providers such as ICON and Thermo Fisher are experiencing second order effects from the difficult funding and political environment.

That notwithstanding, the onward march of larger companies like AstraZeneca implies that there will remain healthy demand for these companies’ services in the years to come. Astra has a massive pipeline of new drugs currently in development, particularly in oncology, where their aim is for 50% of all cancer patients in 2030 to be treated with one of their medications.

While the pharma industry may not yet have found its ‘new normal’, we believe the pressing need for pharmaceutical innovation, and the commercial opportunity for companies like Astra, will create continued healthy demand and profits growth in this industry over the long term.

 

Sign up here to receive our monthly and quarterly commentaries in your inbox.

 

1 https://www.deloitte.com/uk/en/about/press-room/global-pharma-rd-returns-rise-as-one-glp-drugs-help-drive-forecast-growth.html
2 https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025
3 https://www.reuters.com/business/healthcare-pharmaceuticals/trump-administration-health-research-cuts-total-18-billion-analysis-finds-2025-05-08/

Related

Foresight Group LLP completed an acquisition of the trade and assets of WHEB Asset Management LLP (WHEB). By way of Novation, Foresight Group LLP now acts as investment manager. Foresight Group LLP uses the trading names WHEB and WHEB Asset Management.

Foresight Group LLP and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 198020 and has its registered office at The Shard, 32 London Bridge Street, London, SE1 9SG. FundRock Partners Limited (formerly Fund Partners Limited) remains the Authorised Corporate Director of the Funds and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at Hamilton Centre, Rodney Way, Chelmsford, England, CM1 3BY.

Important Notices:

The price of shares (“Shares”) in FP WHEB Sustainability Impact Fund, WHEB Sustainable Impact Fund or WHEB Environmental Impact Fund may increase or decrease and you may not get back the amount originally invested, for reasons including adverse market and foreign exchange rate movements. Past performance does not predict future returns. Any performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. The Fund invests in equities and is exposed to price fluctuations in the equity markets and focuses on investments in mid-sized companies in certain sectors so its performance may not correlate closely with the MSCI World Index (the benchmark). For full risks, please see fund prospectus on www.whebgroup.com. This information is issued by Foresight Group LLP. We have exercised reasonable care in preparing this information including using reliable sources. However, we make no representation or warranty relating to its accuracy, reliability or completeness or whether any future event may or may not occur. The information (including the MSCI information) is intended for information purposes only and does not constitute or form part of any offer or invitation to buy or sell any security. Any opinions constitute our judgment as of the date published and are subject to change without notice. We do not offer legal, tax, financial or investment advice. The information should not be relied upon to make an investment decision. Any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice.

WHEB Environmental Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Fund is registered for distribution to professional investors in the United Kingdom. It is not available to investors domiciled in the United States.

FP WHEB Sustainability Impact Fund

FundRock Partners Limited is the Authorised Corporate Director of the Fund and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at 6th Floor Bastion House, 140 London Wall, London, EC2Y 5DN. The state of the origin of the Fund is England and Wales.

WHEB Sustainable Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The state of the origin of the Fund is Ireland. The Fund is registered for distribution to professional investors in Austria, France, Germany, Italy, Luxembourg, Norway, Singapore, Sweden and the United Kingdom, and is registered for offering to retail investors in Switzerland, Denmark and the Netherlands. The Fund is also available for professional investors in Belgium and Hong Kong. It is not available to investors domiciled in the United States.

For FP WHEB Sustainability Impact Fund and WHEB Sustainable Impact Fund, the Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich.  The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland.

The MSCI information may be used for your internal use, may not be reproduced or re-dissseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

Join our mailing list

Sign up below for regular email updates about our funds, our impact, our events.
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
WHEB is now a part of Foresight Group.
Authorised and regulated by the Financial Conduct Authority
Copyright 2025© WHEB. All rights reserved Made by Thursday